When human insulin is introduced into the C. elegans intestine through feeding bacteria supplemented with a buffered suspension of insulin complexed with protamine sulfate, used to treat type II diabetes in humans, this inhibited α-synuclein aggregation in the muscle through antagonizing the DAF-2/IGFR receptor (Haque et al., 2020). This evidence concerns the gene INS and type 2 diabetes mellitus.